Frankfurt am Main
Germany
44
2025-07-31
The entities that hold a legal rights for patent applications filed by inventor EVERS Andreas:
Andreas EVERS from Frankfurt am Main, DE has applied for patents for these inventions. The list has both pending applications and granted patents:
CRF2 RECEPTOR AGONISTS AND THEIR USE IN THERAPY
#2 | 2024-11-07FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO
#3 | 2024-10-31New Peptides as Potent and Selective GIP Receptor Agonists
#4 | 2023-08-24GLP-1R AGONIST / FGF21 FUSION PROTEINS
#5 | 2023-08-10GLP-1R AGONISTIC PEPTIDES WITH REDUCED ACTIVITY
#6 | 2023-04-06PEPTIDES AS SELECTIVE GIP RECEPTOR AGONISTS
#7 | 2022-12-22FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO
#8 | 2020-08-20Selective glucagon receptor agonists comprising a chelating moiety for imaging purposes
#9 | 2020-08-20FGF21 COMPOUND / GLP-1R AGONIST COMBINATIONS WITH OPTIMIZED ACTIVITY RATIO
#10 | 2020-05-21Conjugates comprising an GLP-1/Glucagon dual agonist, a linker and hyaluronic acid
#11 | 2018-10-11Prodrugs comprising an GLP-1/glucagon dual agonist linker hyaluronic acid conjugate
#12 | 2018-08-23FGF21 compound / GLP-1R agonist combinations with optimized activity ratio
#13 | 2018-07-05Exendin-4 derivatives as dual GLP1/glucagon agonists
#14 | 2018-06-07Compounds as peptidic GLP1/glucagon/GIP receptor agonists
#15 | 2018-06-07Compounds as peptidic trigonal GLP1/glucagon/GIP receptor agonists
#16 | 2018-06-07Conjugates comprising an GLP-1/glucagon dual agonist, a linker and hyaluronic acid
#17 | 2017-08-03Functionalized Exendin-4 derivatives
#18 | 2017-01-26EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
#19 | 2016-09-01Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
#20 | 2016-08-04EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS
#21 | 2016-06-16EXENDIN-4 PEPTIDE ANALOGUES AS DUAL GLP-1/GLUCAGON RECEPTOR AGONISTS
#22 | 2016-05-19Macrocyclic urea derivatives as inhibitors of TAFIa, their preparation and their use as pharmaceuticals
#23 | 2016-01-28Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
#24 | 2015-11-12Peptidic dual GLP-1/glucagon receptor agonists derived from exendin-4
#25 | 2015-11-12Dual GLP-1/glucagon receptor agonists derived from exendin-4
#26 | 2015-11-05Exendin-4 derivatives as peptidic dual GLP-1/glucagon receptor agonists
#27 | 2015-06-18Dual GLP-1/GIP receptor agonists
#28 | 2015-06-18Exendin-4 Peptide Analogues
#29 | 2015-06-18Dual GLP-1/glucagon receptor agonists
#30 | 2015-06-18Non-acylated exendin-4 peptide analogues
#31 | 2015-06-18Exendin-4 peptide analogues as dual GLP-1/GIP receptor agonists
#32 | 2015-05-21Pyrazole derivatives and their use as LPAR5 antagonists
#33 | 2015-05-21Pyridine derivatives and their use in the treatment of conditions associated with pathological thrombus formation
#34 | 2015-04-23Benzo[1,3]dioxine derivatives and their use as LPAR5 antagonists
#35 | 2014-08-07Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists
#36 | 2014-07-31Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists
#37 | 2014-07-24Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
#38 | 2014-07-24Functionalized exendin-4 derivatives
#39 | 2014-07-24Exendin-4 Derivatives
#40 | 2014-04-10Exendin-4 derivatives as dual GLP1/glucagon agonists
#41 | 2014-02-06Macrocyclic urea and sulfamide derivatives as inhibitors of tafia
#42 | 2013-12-19Exendin-4 peptide analogues
#43 | 2011-07-21Macrocyclic urea and sulfamide derivatives as inhibitors of TAFIa
#44 | 2010-02-11Urea and sulfamide derivatives as inhibitors of TAFIa
576136 ⎘